Sigma-Aldrich acquires Seppro depletion technology from GenWay Biotech

16 January 2009

Sigma-Aldrich (NASDAQ:SIAL) has expanded its proteomics offerings with the acquisition of Seppro affinity depletion technology and a library of 700 avian-derived antibodies from GenWay Biotech, Inc.

Seppro depletion products enable scientists to measure more precisely the expression of protein biomarkers from a range of mammalian and plant biological samples. This acquisition covers current inventory, production technology and all future rights to produce and distribute the product lines.

The Seppro IgY depletion platform is an antibody-based technology for processing plasma, serum and plant samples. It enables researchers to detect and analyze commonly obscured biomarkers in samples by removing highly abundant proteins. Seppro depletion products are built using chicken-derived IgY antibodies, providing higher selectivity and lower cross-reactivity than other comparable products.

The Seppro platform, incorporating SuperMix technology, represents the most complete human depletion system available, removing 14 of the most abundant proteins from human serum or plasma, as well as other high and medium abundant proteins. Additional products are available for the depletion of mouse and rat samples, as well as the industry's only depletion system for the removal of Rubisco.

The library of 700 polyclonal IgY antibodies acquired from GenWay represents Sigma-Aldrich's first IgY antibody offering. The new antibodies are derived from chicken embryos and prepared using recombinant antigens. Chicken antibodies display less cross-reactivity with mammalian proteins, producing fewer false positive reactions in certain immunochemical assays. Chicken IgY is also typically more stable than IgG derived from mammalian species.

With the acquisition of the chicken-derived IgY antibodies library, Sigma-Aldrich also plans to expand its antibody catalog, to which more than 8,000 new antibodies were added in 2008.

"The acquisition of Seppro significantly strengthens Sigma-Aldrich's position in antibody-based depletion technology," said Dr. Dave Smoller, President of Sigma-Aldrich's Research Biotech Business Unit. "Our goal, through acquisitions and collaborations, is to provide researchers with the most comprehensive and highly characterized portfolio of antibodies and antibody products."

Seppro technology joins Sigma-Aldrich's leading collection of depletion products, including ProteoPrep kits for the removal of highly abundant proteins, such as albumin and IgG, from human serum and plasma.

Bookmark this page

Your browser does not support inline frames or is currently configured not to display inline frames.	Your browser does not support inline frames or is currently configured not to display inline frames. Sigma-Aldrich acquires Seppro depletion technology from GenWay Biotech 16 January 2009 Sigma-Aldrich (NASDAQ:SIAL) has expanded its proteomics offerings with the acquisition of Seppro affinity depletion technology and a library of 700 avian-derived antibodies from GenWay Biotech, Inc. Seppro depletion products enable scientists to measure more precisely the expression of protein biomarkers from a range of mammalian and plant biological samples. This acquisition covers current inventory, production technology and all future rights to produce and distribute the product lines. The Seppro IgY depletion platform is an antibody-based technology for processing plasma, serum and plant samples. It enables researchers to detect and analyze commonly obscured biomarkers in samples by removing highly abundant proteins. Seppro depletion products are built using chicken-derived IgY antibodies, providing higher selectivity and lower cross-reactivity than other comparable products. The Seppro platform, incorporating SuperMix technology, represents the most complete human depletion system available, removing 14 of the most abundant proteins from human serum or plasma, as well as other high and medium abundant proteins. Additional products are available for the depletion of mouse and rat samples, as well as the industry's only depletion system for the removal of Rubisco. The library of 700 polyclonal IgY antibodies acquired from GenWay represents Sigma-Aldrich's first IgY antibody offering. The new antibodies are derived from chicken embryos and prepared using recombinant antigens. Chicken antibodies display less cross-reactivity with mammalian proteins, producing fewer false positive reactions in certain immunochemical assays. Chicken IgY is also typically more stable than IgG derived from mammalian species. With the acquisition of the chicken-derived IgY antibodies library, Sigma-Aldrich also plans to expand its antibody catalog, to which more than 8,000 new antibodies were added in 2008. "The acquisition of Seppro significantly strengthens Sigma-Aldrich's position in antibody-based depletion technology," said Dr. Dave Smoller, President of Sigma-Aldrich's Research Biotech Business Unit. "Our goal, through acquisitions and collaborations, is to provide researchers with the most comprehensive and highly characterized portfolio of antibodies and antibody products." Seppro technology joins Sigma-Aldrich's leading collection of depletion products, including ProteoPrep kits for the removal of highly abundant proteins, such as albumin and IgG, from human serum and plasma. Bookmark this page Your browser does not support inline frames or is currently configured not to display inline frames. To top	Your browser does not support inline frames or is currently configured not to display inline frames.